The Future of Therapeutic Cloning Discussed at Yale Symposium

Robert Lanza, vice president and medical director of Advanced Cell Technology, Inc., will discuss “The Future of Therapeutic Cloning” in a Bioethics Project Symposium on May 16, from 9:30 a.m. to 3:00 p.m., in Yale’s Luce Hall at 34 Hillhouse Avenue.

Along with a panel of members of the Bioethics Project Stem Cell Working Research Group, Lanza will discuss the nature and future prospects of therapeutic cloning, as well as the significance of stem cell research in comparison with research on adult stem cells.

Advanced Cell Technology, Inc. works to develop technologies that would, through genetic manipulation of an animal’s cells, enable the use of these animals for pharmaceutical protein production. The company also works to develop cloned cells and tissues for use in cell and organ transplantation.

The technologies being developed at Advanced Cell Technology, Inc., may be used to overcome obstacles in the use of transplanted tissue to treat disease. The technologies may prevent transplant rejection, as well as provide a source of cells to meet the demand for large quantities of transplantable tissues.

Lanza is a former Fulbright Scholar and a nominee for the MacArthur Foundation “genius” award, and author of several hundred publications.

For more information, contact Carol Pollard at 203-432-6188, or by e-mail at carol.pollard@yale.edu.

Share this with Facebook Share this with Twitter Share this with LinkedIn Share this with Email Print this